Chemotherapy Effect, G-CHOP Chemotherapy, R-CHOP Chemotherapy
Conditions
Keywords
Haematology, Pharmaceutical Care
Brief summary
Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related Problems (DRPs), and re-hospitalizations. This study aims to evaluate the impact of a multidisciplinary city-hospital follow-up program on medication management safety in haematological oncology patients receiving intravenous chemotherapy in onco-haematology. Additional aspects will be evaluated, such as the impact of the follow-up on the city-hospital link, satisfaction of patients and professionals involved in the follow-up and the use of telecare
Interventions
OTHERAssessment of patient satisfaction regarding tele-consultation
Questionnaire completed following the teleconsultation, if applicable.
OTHERLiteracy questionnaire
Questionnaire completed during hospitalization for the first chemotherapy cycle
OTHERCollection of socio-demographic characteristics
Questionnaire completed during patient hospitalization for the first chemotherapy cycle
OTHERAssessment of patient knowledge on chemotherapy side effects and support medications
Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy
OTHERAssessment of patient satisfaction on pharmaceutical follow-up
Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult patients aged 18 years or older With hematological malignancy at any stage Initiating R-CHOP or G-CHOP chemotherapy Who do not object to participation in the study and use of collected data
Exclusion criteria
* Patients already enrolled in a clinical trial evaluating any drug product * Patients living in an institution * Patients protected by law * Adults subject to a legal protection measure (curatorship, guardianship) (article L1121-8 of the CSP) * Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social establishment (article L1121-6 of the CSP)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the clinical impact of pharmacist interventions at first cycle of chemotherapy, according to the CLEO© scale. | 6 months after inclusion | Each pharmacist intervention performed during patient follow-up will be rated according to its expected level of clinic impact (major, moderate, minor, null) |
Countries
France
Outcome results
None listed